Real-world Clinical Outcomes of Bebtelovimab and Sotrovimab Treatment of High-risk Persons With Coronavirus Disease 2019 During the Omicron Epoch

BACKGROUND: Antispike monoclonal antibodies are recommended for early treatment of high-risk persons with mild to moderate coronavirus disease 2019 (COVID-19). However, clinical outcomes of their use during the severe acute respiratory syndrome coronavirus 2 Omicron wave are limited. METHODS: This i...

Descripción completa

Detalles Bibliográficos
Autores principales: Razonable, Raymund R, Tulledge-Scheitel, Sidna M, Hanson, Sara N, Arndt, Richard F, Speicher, Leigh L, Seville, Teresa A, Larsen, Jennifer J, Ganesh, Ravindra, O’Horo, John C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536189/
https://www.ncbi.nlm.nih.gov/pubmed/36213724
http://dx.doi.org/10.1093/ofid/ofac411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9536189/
https://www.ncbi.nlm.nih.gov/pubmed/36213724
http://dx.doi.org/10.1093/ofid/ofac411

Ejemplares similares